Gillian McGovern, Associate Editor

Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.

The investigators suggested that blocking VPS72’s interactions can be a foundation for future therapeutic interventions.

Compared with standard of care, camizestrant in combination with a CDK4/6 inhibitor shows promise in enhancing progression-free survival (PFS) for patients with advanced breast cancer.

Vadadustat and darbepoetin alfa show similar safety and efficacy in treating CKD-related anemia, with regional differences impacting cardiovascular risks.

CDC urges all US travelers to get vaccinated for measles, mumps, and rubella (MMR) amid rising measles cases, emphasizing prevention as key to combating outbreaks.

New treatments for metabolic dysfunction-associated steatohepatitis (MASH)–related cirrhosis address unique challenges in drug development.

New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC).

A clinical trial shows tebipenem pivoxil hydrobromide (Tebipenem HBr; Spero Therapeutics and GSK) effectively treats complicated urinary tract infections (cUTIs), potentially transforming patient care and reducing hospital costs.

A study reveals a 14-gene assay guides chemotherapy decisions effectively in patients with early-stage non-small cell lung cancer (NSCLC).

Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.

Researchers explore cellular senescence's role in kidney fibrosis, highlighting potential therapies to combat chronic kidney disease progression.

The test offers health care professionals a simple and efficient method of identifying patients with liver fibrosis of varying severity.

Shore Medical Center enhances patient safety with a pharmacy-driven intravenous to oral opioid conversion protocol, minimizing risks and improving pain management.

The investigators suggest that early detection and treatment of chronic kidney disease (CKD) in childhood cancer survivors may decrease late complications and mortality.

The formulation allows for individualized treatment in children with adrenocortical insufficiency.

The small molecule effectively blocks cell death effector proteins, potentially rescuing cells from degeneration.

The approval is based on findings from the INSPIRE trial, where treprostinil demonstrated efficacy in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The authors are optimistic that GADD45A serves as a foundation for therapeutic approaches to slow the progression of heart failure.

After 3 predictive mortality tools demonstrate inefficiency within older adults with advanced chronic kidney disease (CKD), the authors call for the development of tools tailored for this population.

This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body.

The phase 3 REAL8 trial shows once-weekly Sogroya effectively improves growth in children with growth disorders, offering a promising alternative to daily injections.

The risk of cardiovascular disease (CVD) was higher among those who were exposed to assisted reproductive technology.

Compared with placebo, patients with cholestatic pruritus and primary biliary cholangitis (PBC) receiving linerixibat experienced improved itch and sleep interference.

The authors believe the results may serve as a foundation for hepatitis D virus (HDV) testing among hepatitis B virus surface antigen (HBsAg)-positive specimens.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The new guidelines urge health care professionals to offer local anesthetics and other medications for intrauterine device (IUD) insertions and other gynecologic procedures.

The FDA approves retifanlimab for advanced anal cancer, offering new hope with improved survival rates and treatment options for patients.

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.

The announcement came shortly before updated results from the SURMOUNT-5 clinical trial, which found Zepbound had superior weight-loss effects over Wegovy.

Effectively communicating research findings to patients, health care professionals, and policy payers is necessary for engagement.